BridgeBio Oncology Therapeutics Inc. (BBOT) vs EyePoint Pharmaceuticals, Inc. (EYPT)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and EyePoint Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
EYPT
EyePoint Pharmaceuticals, Inc.
$3.17HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BBOT vs EYPT
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)EYPT -89.1% (-52.2%/yr)BBOT compounded faster over this window
BBOT EYPT
BBOT vs EYPT: by the numbers
- •BBOT is the larger company ($280M vs $266M market cap).
- •Both run net losses; BBOT's is the smaller (0.00% vs -10994.73% net margin).
Metrics side by side
Valuation
| Metric | BBOT | EYPT |
|---|---|---|
| P/S ratio | N/A | 95.29 |
| P/B ratio | 0.87 | 1.60 |
Profitability
| Metric | BBOT | EYPT |
|---|---|---|
| Gross margin | 0.00% | 93.41% |
| Operating margin | 0.00% | -775.98% |
| Net margin | 0.00% | -10994.73% |
| ROE | -56.36% | -184.27% |
| ROIC | -61.10% | -170.19% |
Growth (annualized)
| Metric | BBOT | EYPT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -41.05% |
| Total return CAGR (5Y) | N/A | -21.68% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROEEyePoint Pharmaceuticals ROEBridgeBio Oncology Therapeutics operating marginEyePoint Pharmaceuticals operating marginBridgeBio Oncology Therapeutics revenue growthEyePoint Pharmaceuticals revenue growthBridgeBio Oncology Therapeutics free cash flowEyePoint Pharmaceuticals free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.